The effect of a single therapeutic dose of cisplatin on GFR in dogs.
This study prospectively describes the late effect of a single dose of cisplatin on GFR in tumor-bearing dogs. GFR (measured by quantitative renal scintigraphy), BUN, creatinine, and urine specific gravity values were obtained in 19 tumor-bearing dogs prior to and four weeks after a single dose of cisplatin. Eleven tumor-bearing dogs were given a known non-nephrotoxic anticancer drug, dexniguldipine, as control. No significant differences in pretreatment GFR, serum chemistry, or urinalysis values were observed between cisplatin-treated and control dogs. GFR was significantly decreased four weeks following cisplatin administration. The average percent change in GFR was -13.49% for all cisplatin treated dogs. No significant alterations of BUN, serum creatinine, or urine specific gravity were observed following treatment. In the control group, the average percent change in GFR was +3.98% which was not significantly different from pretreatment values.